BNGO News & Events

Hopes for de-escalation in the Middle East conflict helped restore positive sentiment as President Trump's Truth Social post that strikes on Iranian energy infrastructure would be postponed after "productive" talks with Tehran boosted equities and dented geopolitical premium in the energy markets.  Consumer Discretionary and Materials were the best performing areas on the benchmark S&P 500, though all 11 sectors ended Monday in the positive - including Energy in spite of Oil prices falling back below $90 per barrel.  In the opening hour of the evening session, S&P 500 futures  are up another 0.2% and Nasdaq 100 is trading up 0.3% while WTI Crude is just off the closing lows above $89.  In precious metals, risk aversion which had boosted USD and punished Gold and Silver prices has reversed, and the two contracts are trading firmer around $4.435 and $70 per ounce respectively.Among the key headlines of the afterhours session continued to remind investors that the primary source of concern are still present.  Core Labsissued a below-consensus Q1 pre-announcement as the company cited regional instability in the Middle East, including client-driven project delays, travel constraints, and supply-chain disruptions. Private Credit worries also cropped up via reports from Bloomberg stating that Apollo Globalhas joined some of the other asset managers in capping private equity redemptions due to high volume of requests by investors to liquidate their positions.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -BARKup 6.4%Bionano Genomicsup 4.1%DOWN AFTER EARNINGS -Core Laboratoriesdown 1.8% after Q1 pre-announcementAardvark Therapeuticsdown 1.5%ALSO LOWER -Comtech Telecommunicationsdown 3.9% after equity offeringApollo Global Managementdown 2.1% after Bloomberg report of capped private equity redemptions

Sees FY26 revenue $30M-$33M.

"2025 demonstrated the momentum we built as a business," commented Erik Holmlin, president and CEO of Bionano. "Our routine users of optical genome mapping and VIA software remain the foundation of our revenue and gross margins, and we are pleased to see continued growth in utilization among this core customer base. The global OGM community continues to show extraordinary energy, from the record attendance and engagement at the Bionano Symposium 2026 - where leading laboratories described scaling OGM workflows to potentially thousands of samples per year - to the continued expansion of the published body of clinical research evidence supporting OGM across hematologic malignancies, constitutional genetics, and cell and gene therapy applications. We also saw the 47% increase in the 2026 Clinical Lab Fee Schedule payment determination for the Category I CPT code for OGM use in hematologic malignancies take effect. Together, these developments reinforce our confidence that OGM is becoming the standard for comprehensive, genome-wide structural variant analysis, and that Bionano is well-positioned to drive continued utilization growth and sustainable progress in 2026."

Bionano Genomics announced highlights from the fourth and final day of Symposium 2026. Day 4 featured updates from some of the most advanced and high-volume cytogenetics and molecular pathology laboratories in the United States, Canada and Europe describing how they envision scaling optical genome mapping, including processing up to thousands of samples per year with automation, multiple OGM systems, and VIA software. Other talks covered topics like Bionano's Ionic system for isolating DNA and RNA for next generation sequencing and advanced analytical tools that could be the future of digital cytogenetics and molecular pathology by enabling digital karyotype construction.